cyclophosphamide (nanoparticle reformulation)

Prosemble's nanoparticle reformulation of cyclophosphamide is a preclinical-stage antineoplastic agent designed to improve the delivery of the classic alkylating chemotherapy drug. By utilizing nanoparticle technology, the formulation aims to alter the pharmacokinetic profile of cyclophosphamide, potentially reducing systemic toxicities such as myelosuppression and hemorrhagic cystitis while maintaining or enhancing therapeutic efficacy. Cyclophosphamide itself is a prodrug that is metabolized into active alkylating agents that cross-link DNA, thereby inhibiting DNA replication and inducing apoptosis in rapidly dividing cancer cells. This reformulation is being developed for a broad range of indications, including leukaemia, lymphoma, breast cancer, ovarian cancer, and various childhood cancers.

Other names

Cyclophosphamide nanoparticle formulationReformulated cyclophosphamide